

REMARKS

Claims 1 and 3 have been amended in order to write these claims in the appropriate U.S. claim format.

Claim 2 has been canceled.


Claims 4-6 have been added by the foregoing amendments. Support for claim 4 occurs, for example, at page 9 of the specification. Support for claims 5-6 occurs, for example, at page 12, lines 1-3 of the specification.

Claims 1 and 3-6 remain in the application.

Attached hereto is a marked-up version of the changes made to the claims by the instant amendment. The marked-up version is entitled "Version With Markings To Show Changes Made".

Respectfully submitted,

Date: September 20, 2001



Michael D. Alexander
Reg. No. 36,080

Address
Patent Department
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
Malvern, PA 19355
Telephone No. (610) 889-8802
Facsimile: (610) 889-8799

Version With Markings to Show Changes MadeIn the Claims:

Claims 1 and 3 have been amended as follows:

1. (amended) A compound ~~Compound~~ corresponding to the general formula (I)



in which

X represents an oxygen atom or a group of formula NZ in which Z represents a hydrogen atom or a (C₁-C₆)alkyl group,

n represents a number 0, 1 or 2, and

R₁, R₂, R₃, R₄ and R₅ each represent, independently of each other, a hydrogen or halogen atom or a trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, phenoxy or phenyl group optionally substituted with a halogen atom or a trifluoromethyl, cyano, hydroxyl, (C₁-C₆)alkyl or (C₁-C₆)alkoxy group, or alternatively R₂ and R₃ together form a group of formula -OCH₂O- or -CH₂CH₂CH₂CH₂-, in the form of a base or of an addition salt with an acid.

3. (amended) A pharmaceutical ~~Pharmaceutical~~ composition, ~~characterized in that it contains~~ comprising a compound according to Claim 1, combined with an excipient.

Claim 2 has been canceled.

Claims 4-6 have been added.